LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer
Clinical and Translational Medicine2022Vol. 12(4), pp. e792–e792
Citations Over TimeTop 10% of 2022 papers
Yanping Gao, Nannan Zhang, Zihang Zeng, Qiuji Wu, Xueping Jiang, Shuying Li, Wenjie Sun, Jianguo Zhang, Yangyi Li, Jiali Li, Fajian He, Zhengrong Huang, Jinfang Zhang, Yan Gong, Conghua Xie
Abstract
PCAT1/SOX2 axis promoted tumorigenesis and immunosuppression through inhibition of cGAS/STING signalling-mediated T-cell activation. Inhibition of PCAT1 and SOX2 synergised with radiotherapy to activate the immune response and could serve as potential therapeutic targets.
Related Papers
- → Knockdown of LIMD2 inhibits the progression of ovarian carcinoma through ERK1/2 pathway(2023)2 cited
- → Knockdown of ecdysteroid synthesis genes results in impaired molting and high mortality in Bactericera cockerelli (Hemiptera: Triozidae)(2022)9 cited
- → Supplementary Revised Figure S3 from MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53(2023)
- → Supplementary Revised Figure S4 from MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53(2023)
- → Supplementary Revised Figure S3 from MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53(2023)